Current Therapeutic Limitation
Chemotherapeutic agents are the most commonly administered drugs to treat cancer, the second leading cause of death in the United States. Unfortunately, a vast majority of systemically administered chemotherapy is not delivered to the target tumor site. Off-target chemotherapeutic agents that remain in the patient’s bloodstream are more likely to contribute to increased toxicity versus patient benefit.
To overcome this limitation, we designed a therapeutic system comprised of ChemoPrepTM to enhance the tumor site delivery of chemotherapy and ChemoPureTM to reduce its toxicity.
Once initial tumor saturation has been achieved, ChemoPureTM offers to reduce treatment toxicity by depleting the presence of bloodstream chemotherapeutic agents before they induce the death of healthy non-tumor cells. Decreased toxicity may also alleviate treatment-related fatigue and potentially mitigate long-term health consequences that can result from chemotherapy administration.
Based on the increasing prevalence of cancer, analysts at Data Bridge Market Research project the global market for chemotherapeutic drugs will increase from $42.9 billion in 2021 to $89.3 billion in 2029. ChemoPureTM
establishes a candidate strategy to reduce the toxicity of these chemotherapy agents.
If demonstrated to be clinically effective, ChemoPureTM would overcome a therapeutic limitation in healthcare and likely provide a competitive advantage to organizations focused on the commercialization of cancer chemotherapies.
ChemoPureTM is associated with a provisional patent submission entitled: “SYSTEM AND METHODS TO ENHANCE CHEMOTHERAPY DELIVERY AND REDUCE TOXICITY” that has been filed with the United States Patent and Trademark Office (“USPTO”).